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 シトレオビリジン（CTVD）は、Penicillium citreonigrum、Aspergillus 
terreus、Eupenicillium ochrosalmoneum などが二次代謝産物として産
生するカビ毒である。CTVD を産生する P. citreonigrum などは穀類の
うち主にコメを汚染するため、コメを主食とするアジアや南米などの
国々で CTVD の汚染は問題となる。CTVD に汚染されたコメが黄色くな
ることから、CTVD は黄変米毒の一つとしても知られており、日本国内
で過去に輸入米での汚染事例が報告されている。近年においても、タイ
やブラジ ルなど 熱帯性気 候の地 域で CTVD 産生 能 を有す る P. 
citreonigrum の存在が報告されている。  







LD50 は 3.6-11.8 mg/kg(皮下投与 )、7.5 mg/kg(腹腔内投与 )とされている。
ヒトで起こる健康被害としては、衝心脚気や Keshan 病との関連も指摘
されており、2006 年にブラジルで発生した衝心脚気のアウトブレイクで
は、当該地域のコメから CTVD を産生する P. citreonigrum が検出されて
おり、同毒素が原因物質として疑われている。  
 毒性学研究においてはトキシコキネティクスや体内動態の情報が欠








験を in vitro で行い、ヒトにおける CTVD のバイオアベイラビリティを
推測した。本研究の概要は次のとおりである。  
 
Ⅰ  ブタにおける CTVD のトキシコキネティクス  
 約 10 kg のブタに CTVD 0.1 mg/kg bw を静脈投与及び経口投与した。
継時的に血液を採取し、分離した血漿中の CTVD 濃度を LC-MS/MS で分
析した。分析結果から解析ソフト (WinNonlin)を用いてトキシコキネティ
クスパラメータ (TK パラメータ )を算出し、次の結果を得た。（１）静脈
投与後の CTVD の血漿中濃度は、投与後急激に減少し、最終採血時点で
ある 48 時間後まで緩やかに減少したが 48 時間後でも血漿中から CTVD
が検出された。（２）静脈投与時の TK パラメータは、小さな速度定数（Kel）
（0.5 ± 0.1 ×10 -1 h-1）を示し、半減期（T1/2）及び分布容積（Vd）は
それぞれ 16.2 ± 4.3 h、1.5 ± 0.2 L であった。（３）経口投与後の CTVD
の血漿中濃度は、投与後緩やかに上昇し、15.0 ± 6.0 h（Tmax）でピー
ク（Cmax：38.2 ±6.7 ng/mL）を迎えたのち、48 時間後まで緩やかに減
少した。（４）経口投与時の TK パラメータは、静脈投与と同様に Kel が
小さく（0.4±0.2 ×10-1 h-1）、比較的長い T1/2（21.4 ± 12.7 h）と大きな
Vd（1.7 ± 0.3 L）を示した。（５）CTVD のブタにおけるバイオアベイ






Ⅱ  ヒト腸管培養細胞 Caco-2 細胞を用いた CTVD の透過係数  
 ヒトにおける CTVD のバイオアベイラビリティを推定するため、ヒト
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腸管細胞モデルである Caco-2 細胞を用いた透過実験を実施した。
CorningTM BioCoatTM Intestinal Epithelium Differentiation Environment Kit
を用い、単層に培養した Caco-2 細胞の粘膜面側に CTVD（3 uM 及び 10 uM）
を暴露し、37℃でインキュベートした。2 時間後の粘膜面側及び基底膜
面側の培地を採取し、培地中の CTVD 濃度を LC-MS/MS を用いて測定し
て、経上皮電気抵抗値（TEER）及び透過係数（Papp）を求めた。その結
果、（１）いずれの CTVD 濃度においても TEER に変化は認められなか
った。（２）各 CTVD 濃度における Papp は、それぞれ 52.2 ± 28.3、42.6 





Ⅲ  ブタ及びヒト肝臓 S9 画分を用いた CTVD の代謝とその代謝物  





び NADP を含む溶液中に肝臓 S9 画分（0.5 mg/mL）及び CTVD（1.5 ug/mL）
を加え、37℃でインキュベートした。インキュベート後 30 分、1 時間及




CTVD 濃度がブタ肝臓 S9 画分を用いるよりもヒト肝臓 S9 画分を用いた






在下で CTVD と S9 画分をインキュベートして、CTVD のグルクロン酸
抱合体の産生を調べた。その結果、（１）いずれの S9 画分を用いた場合
でも、インキュベート後 30 分までに CTVD のグルクロン酸抱合体は産
















Citreoviridin (CTVD) is a mycotoxin that is a secondary metabolite produced 
by Penicillium citreonigrum, Aspergillus terreus and Eupenicillium ochrosalmoneum. 
Because P. citreonigrum capable of producing CTVD contaminates mainly rice, 
contamination with CTVD can be problem in countries of Asia and South America, 
where rice is a staple food. CTVD is a yellow rice toxin, and a case of its 
contamination in an imported rice sample was previously reported in Japan. Recently, 
the occurrence of P. citreonigrum capable of producing CTVD has been reported in 
areas with a tropical climate, such as Thailand and Brazil. 
Regarding toxicity of CTVD, in the 1940s, several toxicological studies 
revealed that symptoms such as progressive paralysis, vomiting, convulsions and 
temporary respiratory disturbance developed when a crude extract from contaminated 
rice was administered to mammals and other vertebrates via intraperitoneal (IP), 
subcutaneous (SC) and oral (PO) routes. Furthermore, it was found that isolated 
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CTVD causes the same symptoms as experiments using moldy rice. Neurological 
symptoms progressed faster at higher doses of extracted toxin, and the median lethal 
dose (LD50) of CTVD for mice has been reported be 3.6 to 11.8 mg/kg (SC) and 7.5 
mg/kg (IP). As a human adverse effects, CTVD has been considered to be related to 
Shoshin-kakke (acute cardiac beriberi) and Keshan disease which adversely affects 
the heart. In 2006, an outbreak of Shoshin-kakke occurred in Brazil, and the presence 
of rice contaminated with P. citreonigrum capable of producing CTVD was reported 
in the outbreak area. 
An understanding of toxicokinetics is essential when performing a 
toxicological study. However, from the 1940s to the 1980s, when toxicological 
studies of CTVD were performed actively, no high-resolution analytical methods had 
yet been developed, and the toxicokinetics of CTVD were determined based solely on 
the results of a fluorescence analysis using thin layer chromatography. 
The present study was conducted with the following three experiments: (1) the 
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toxicokinetics of CTVD were investigated by administering CTVD to swine, which 
are similar to humans both anatomically and physiologically; (2) the permeability of 
CTVD was investigated using Caco-2 cells, which are a model of human intestinal 
cells; and (3) a CTVD metabolic study was conducted using the swine or human 
hepatic S9 fraction containing metabolic enzymes.  
The bioavailability of CTVD to humans was estimated, while in addition the 
toxicokinetics of CTVD  in vitro to humans was compared with that to swine on 
studies (2) and (3).  
I. Toxicokinetics of CTVD in swine 
CTVD (0.1 mg/kg body weight) was administered to swine (weighing about 
10 kg) intravenously (IV) and PO. The CTVD concentration of plasma samples was 
determined via liquid chromatography with tandem mass spectrometry (LC-MS/MS). 
The toxicokinetics parameters (TK) were analyzed, and the following results were 
obtained: (1) the CTVD concentration in plasma decreased quickly shortly after IV 
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administration and then continued to decrease moderately until 48 h (final sampling 
point); however, some amount of CTVD remained in plasma even at 48 h after 
administration. (2) The rate constant (Kel) after IV administration was 0.5 ± 0.1 × 10 
-1 h-1. The half-life (T1/2) and volume of distribution (Vd) were 16.2 ± 4.3 h and 1.5 ± 
0.2 L, respectively. (3) The CTVD concentration in plasma in PO gently increased 
after administration and reached the maximum concentration (Cmax: 38.2 ± 6.7 
ug/mL) at 15.0 ± 6.0 h (Tmax), after which it moderately decreased until 48 h. (4) The 
Kel after PO administration was small (0.4 ± 0.2 × 10-1 h-1, similar to that in IV). The 
T1/2 and Vd were 21.4 ± 12.7 h and 1.7 ± 0.3 L, respectively. (5) The bioavailability 
of CTVD was 79.3% from 0 to 48 h and 116.4% on extrapolating from 48 h to 
infinity. These results suggested that CTVD had a high bioavailability in swine. In 
addition, CTVD was eliminated slowly from the body and was easily distributed to 
tissues. These findings suggested that CTVD remained in the body for a relatively 
long time after administration. 
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II. Permeability of CTVD for Caco-2 cells, a human intestinal cell model 
Because CTVD had a relatively high bioavailability in swine, a permeability 
study was performed using Caco-2 cells, which are a human intestinal cell model. 
CTVD (3 μM and 10 μM) was treated to the apical side (AP) of Caco-2 cells cultured 
in a monolayer using a CorningTM BioCoatTM Intestinal Epithelium Differentiation 
Environment Kit (Corning, NY, USA) and then incubated at 37 °C. After 2 h, the 
culture medium was sampled from the AP and basolateral side (BL). The CTVD 
concentration was determined using LC-MS/MS, and then the transepithelial 
electrical resistance (TEER) and permeability coefficient (PaPP) were estimated. The 
results of this study were as follows: (1) The TEER was unchanged at each 
concentration of CTVD. (2) The PaPP values at each CTVD concentration of 3 μM 
and 10 μM were 52.2 ±28.3 and 42.6 ± 17.7 (×10-6 cm/s), respectively, indicating a 
relatively high permeability. These findings suggested that CTVD could be easily 
absorbed by the human intestine, similar to swine, which reflected a high lipid 
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solubility of CTVD. 
III. CTVD metabolism and its metabolites as assessed using swine and human 
hepatic S9 fractions 
Our in vivo study showed that the plasma CTVD concentration decreased 
gently, and CTVD was still detected even at 48 h after administration. Given these 
results, the CTVD metabolism was next investigated using swine and human hepatic 
S9 fractions containing metabolic enzymes. CTVD was incubated at 37 °C with 
hepatic S9 fraction in solution containing glucose-6-phosphate (G6P) and NADP. The 
solution was sampled at 30 min, 1 and 4 h after incubation, and then the 
concentrations of CTVD and its metabolites were determined using a quadrupole 
time-of-flight mass spectrometer (Q-TOF). The findings were as follows: (1) The 
CTVD metabolites were estimated to be hydroxylation-methylation, desaturation and 
dihydoroxylation derivatives. (2) Each metabolite was produced in greater quantities 
using the human hepatic S9 fraction than the swine hepatic S9 fraction. (3) The 
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CTVD concentration was significantly lower with the human hepatic S9 fraction than 
with the swine hepatic S9 fraction. These results suggested that CTVD was slowly 
metabolized in swine, which may have been the cause of the slow elimination rate 
noted in the swine in the in vivo study. In addition, humans seemed to more readily 
metabolize CTVD than swine. 
Because CTVD glucuronide was unable to be detected in the metabolic study 
using S9 fractions in the presence of G6P and NADP, CTVD was incubated with an 
S9 fraction in the presence of UDP-glucuronic acid and alamethicin to examine 
CTVD glucuronidation ability. The following results were obtained: (1) CTVD 
glucuronide had not been produced by 30 min after incubation, regardless of the 
fraction used. (2) The levels of CTVD glucuronide at 4 h after incubation were 
significantly greater with the swine hepatic S9 fraction than with the human hepatic 
S9 fraction. These findings suggested that CTVD glucuronide was more readily 
produced in swine than in humans. 
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The present studies showed that CTVD is easily absorbed by the body and has 
a long T1/2 and large Vd, indicating that CTVD persists for a relatively long time in 
the body. In addition, the bioavailability of CTVD appeared to be high in both 
humans and swine. Regarding CTVD metabolism, humans were able to metabolize 
CTVD earlier than swine according to in vitro findings, while the glucuronidation 
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